Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: A Korean Perspective.
10.3346/jkms.2005.20.6.913
- Author:
Won Jung KOH
1
;
O Jung KWON
;
Kyung Soo LEE
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ojkwon@smc.samsung.co.kr
- Publication Type:Review ; Research Support, Non-U.S. Gov't
- Keywords:
Mycobacteria, Atypical;
Mycobacterium avium Complex;
Mycobacterium abscessus;
Mycobacterium kansasii, Epidemiology;
Diagnosis;
Antibiotics, Antitubercular;
Korea
- MeSH:
Anti-Bacterial Agents/therapeutic use;
Female;
Humans;
Korea;
Lung Diseases/*diagnosis/drug therapy/microbiology;
Male;
Mycobacterium Infections, Atypical/*diagnosis/drug therapy/microbiology;
Mycobacterium avium-intracellulare Infection/diagnosis/drug therapy/microbiology;
Research Support, Non-U.S. Gov't
- From:Journal of Korean Medical Science
2005;20(6):913-925
- CountryRepublic of Korea
- Language:English
-
Abstract:
The incidence of pulmonary disease caused by nontuberculous mycobacteria (NTM) appears to be increasing worldwide. In Korea, M. avium complex and M. abscessus account for most of the pathogens encountered, whilst M. kansasii is a relatively uncommon cause of NTM pulmonary diseases. NTM pulmonary disease is highly complex in terms of its clinical presentation and management. Because its clinical features are indistinguishable from those of pulmonary tuberculosis and NTMs are ubiquitous in the environment, the isolation and identification of causative organisms are mandatory for diagnosis, and some specific diagnostic criteria have been proposed. The treatment of NTM pulmonary disease depends on the infecting species, but decisions concerning the institution of treatment are never easy. Treatment requires the use of multiple drugs for 18 to 24 months. Thus, treatment is expensive, often has significant side effects, and is frequently not curative. Therefore, clinicians should be confident that there is sufficient pathology to warrant prolonged, multidrug treatment regimens. In all of the situations, outcomes can be best optimized only when clinicians, radiologists, and laboratories work cooperatively.
